Choice of management of southern Chinese BRCA mutation carriers

World Journal of Surgery

Volumn 34, Issue 7, 2010, Pages 1416-1426

  Kwong, Ava ^a,b,c,d   Wong, Connie H N ^a,c   Shea, Catherine ^a   Suen, Dacita T K ^a,c   Choi, Catherine L Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^c Hong Kong Hereditary Breast Cancer Family Registry   (Hong Kong)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST TUMOR; CLINICAL TRIAL; FEMALE; GENETIC COUNSELING; GENETICS; HEALTH SURVEY; HETEROZYGOTE; HUMAN; MALE; MASTECTOMY; MULTICENTER STUDY; OVARIECTOMY; OVARY TUMOR; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE; UTERINE TUBE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; HETEROZYGOTE; HUMANS; MALE; MASTECTOMY; OVARIAN NEOPLASMS; OVARIECTOMY; POPULATION SURVEILLANCE; RISK ASSESSMENT;

EID: 77955469386     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-010-0477-5     Document Type: Article

References (84)

1. A Antoniou, et al. 2003 Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 5 1117 1130 10.1086/375033 1:CAS:528:DC%2BD3sXjslagtbg%3D 12677558 (Pubitemid 36530000)
2. MC King JH Marks JB Mandell 2003 Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 5645 643 646 10.1126/science.1088759 1:CAS:528:DC%2BD3sXotlWqt7Y%3D 14576434 (Pubitemid 37310920)
3. EB Claus, et al. 1996 The genetic attributable risk of breast and ovarian cancer Cancer 77 11 2318 2324 10.1002/(SICI)1097-0142(19960601)77:11<2318:: AID-CNCR21>3.0.CO;2-Z 1:STN:280:DyaK283isV2jsg%3D%3D 8635102 (Pubitemid 26162426)
4. D Ford, et al. 1998 Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium Am J Hum Genet 62 3 676 689 10.1086/301749 1:CAS:528:DyaK1MXlvFeh 9497246 (Pubitemid 28164626)
5. MA Bollet, et al. 2007 Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first Radiother Oncol 82 3 272 280 10.1016/j.radonc.2007.01.001 17287037 (Pubitemid 46350796)
6. HB Mohamad JP Apffelstaedt 2008 Counseling for male BRCA mutation carriers: a review Breast 17 5 441 450 10.1016/j.breast.2008.05.001 18657973
7. T Kirchhoff, et al. 2004 BRCA mutations and risk of prostate cancer in Ashkenazi Jews Clin Cancer Res 10 9 2918 2921 10.1158/1078-0432.CCR-03-0604 1:CAS:528:DC%2BD2cXjs12lsL4%3D 15131025 (Pubitemid 38619665)
8. TR Rebbeck, et al. 2004 Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group J Clin Oncol 22 6 1055 1062 10.1200/JCO.2004.04.188 14981104 (Pubitemid 41095038)
9. H Meijers-Heijboer, et al. 2001 Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 345 3 159 164 10.1056/NEJM200107193450301 1:CAS:528:DC%2BD3MXlslSlt7g%3D 11463009 (Pubitemid 32662123)
10. TR Rebbeck, et al. 2002 Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 21 1616 1622 10.1056/NEJMoa012158 12023993 (Pubitemid 34755669)
11. ND Kauff, et al. 2002 Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 21 1609 1615 10.1056/NEJMoa020119 12023992 (Pubitemid 34755668)
12. Society of Gynecologic Oncologists Committee (2005) Society of gynecologic oncologists clinical practice committee statement on prophylactic salpingo-oophorectomy. Gynecol Oncol 98(2):179-181
13. MB Daly 2006 Tamoxifen in ductal carcinoma in situ Semin Oncol 33 6 647 649 10.1053/j.seminoncol.2006.08.019 17145343 (Pubitemid 44828130)
14. SA Narod, et al. 2002 Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers J Natl Cancer Inst 94 23 1773 1779 1:CAS:528:DC%2BD38XptlOitLo%3D 12464649
15. VG Vogel 2009 The NSABP study of tamoxifen and raloxifene (STAR) trial Expert Rev Anticancer Ther 9 1 51 60 10.1586/14737140.9.1.51 1:CAS:528:DC%2BD1cXhsFequ7jK 19105706
16. MJ Bermejo-Perez S Marquez-Calderon A Llanos-Mendez 2007 Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review Int J Cancer 121 2 225 231 10.1002/ijc.22817 1:CAS:528:DC%2BD2sXmslOltr4%3D 17471565 (Pubitemid 46917689)
17. GH Sakorafas 2003 The management of women at high risk for the development of breast cancer: risk estimation and preventative strategies Cancer Treat Rev 29 2 79 89 10.1016/S0305-7372(02)00107-X 12670450 (Pubitemid 36519389)
18. B Fisher, et al. 2005 Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study J Natl Cancer Inst 97 22 1652 1662 10.1093/jnci/dji372 1:CAS:528:DC%2BD2MXht1entb7L 16288118 (Pubitemid 41672231)
19. N Houssami J Cuzick JM Dixon 2006 The prevention, detection, and management of breast cancer Med J Aust 184 5 230 234 16515434
20. SR Cummings, et al. 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation JAMA 281 23 2189 2197 10.1001/jama.281.23. 2189 1:CAS:528:DyaK1MXktFGitL0%3D 10376571 (Pubitemid 29275701)
21. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The cancer and steroid hormone study of the centers for disease control and the national institute of child health and human development. N Engl J Med 316(11):650-655 (1987)
22. S Brown, et al. 2009 Initial radiation experience evaluating early tolerance and toxicities in patients undergoing accelerated partial breast irradiation using the contura multi-lumen balloon breast brachytherapy catheter Brachytherapy 8 2 227 233 10.1016/j.brachy.2008.11.013 19217353
23. W Burke, et al. 1997 Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer genetics studies consortium JAMA 277 12 997 1003 10.1001/jama.277.12.997 1:STN:280:DyaK2s3ivVSguw%3D%3D 9091675 (Pubitemid 27142370)
24. M Kriege, et al. 2004 Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition N Engl J Med 351 5 427 437 10.1056/NEJMoa031759 1:CAS:528:DC%2BD2cXmtFalu7o%3D 15282350 (Pubitemid 38988592)
25. MJ Stoutjesdijk, et al. 2001 Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer J Natl Cancer Inst 93 14 1095 1102 10.1093/jnci/93.14.1095 1:STN:280:DC%2BD3MvisVamuw%3D%3D 11459871
26. MO Leach, et al. 2005 Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) Lancet 365 9473 1769 1778 10.1016/S0140-6736(05)66481-1 1:STN:280:DC%2BD2M3mvFCqtg%3D%3D 15910949 (Pubitemid 40744657)
27. E Warner, et al. 2004 Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination JAMA 292 11 1317 1325 10.1001/jama.292.11.1317 1:CAS:528: DC%2BD2cXns12rs78%3D 15367553 (Pubitemid 39223222)
28. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 55(3 Pt 2):S4-S14 (1994)
29. A Dorum, et al. 1999 Prospectively detected cancer in familial breast/ovarian cancer screening Acta Obstet Gynecol Scand 78 10 906 911 10.1080/j.1600-0412.1999.781013.x 1:STN:280:DC%2BD3c%2FktlGmtg%3D%3D 10577622
30. S Wainberg J Husted 2004 Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation Cancer Epidemiol Biomarkers Prev 13 12 1989 1995 1:CAS:528:DC%2BD2cXhtVOjsLrE 15598752
31. SM Domchek, et al. 2006 Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study Lancet Oncol 7 3 223 229 10.1016/S1470-2045(06)70585-X 1:CAS:528:DC%2BD28XitVeitLs%3D 16510331 (Pubitemid 43286452)
32. KA Metcalfe, et al. 2008 International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers Int J Cancer 122 9 2017 2022 10.1002/ijc.23340 1:CAS:528:DC%2BD1cXkt1ChsL8%3D 18196574 (Pubitemid 351441190)
33. D Ford, et al. 1994 Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium Lancet 343 8899 692 695 10.1016/S0140-6736(94)91578-4 1:STN:280:DyaK2c7otVKitQ%3D%3D 7907678 (Pubitemid 24087847)
34. DF Easton, et al. 1997 Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13 Am J Hum Genet 61 120 128 10.1086/513891 1:STN:280:DyaK2szovVOmuw%3D%3D 9245992
35. JP Struewing, et al. 1997 The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 20 1401 1408 10.1056/NEJM199705153362001 1:STN:280:DyaK2s3nsVShug%3D%3D 9145676 (Pubitemid 27208598)
36. JL Hopper, et al. 1999 Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian breast cancer family study Cancer Epidemiol Biomarkers Prev 8 9 741 747 1:CAS:528:DyaK1MXmsFGktL4%3D 10498392
37. F Podo, et al. 2002 The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk J Exp Clin Cancer Res 21 3 Suppl 115 124 1:STN:280: DC%2BD3s%2FnsVGlsw%3D%3D 12585665
38. ND Kauff, et al. 2008 Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study J Clin Oncol 26 8 1331 1337 10.1200/JCO.2007.13. 9626 18268356
39. M Fatouros G Baltoyiannis DH Roukos 2008 The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations Ann Surg Oncol 15 1 21 33 10.1245/s10434-007-9612-4 17940826
40. SM Domchek JE Stopfer TR Rebbeck 2006 Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers J Natl Compr Canc Netw 4 2 177 182 16451773
41. I Milsom V Odlind 2008 Oral contraceptives give long-lasting protection against ovarian cancer. Use of oral contraceptives can explain reduced incidence of ovarian cancer in Sweden Lakartidningen 105 10 715 716 18422235
42. D Bonn 2002 Prostate-cancer screening targets men with BRCA mutations Lancet Oncol 3 12 714 10.1016/S1470-2045(02)00950-6 12473505
43. VN Giri, et al. 2007 Prostate cancer risk assessment program: a 10-year update of cancer detection J Urol 178 5 1920 1924 10.1016/j.juro.2007.07.010 1:CAS:528:DC%2BD2sXht12rtrvP 17868726 (Pubitemid 47538590)
44. SK Basu, et al. 2008 Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease Int J Radiat Oncol Biol Phys 72 1 34 40 18722264
45. A Kwong, et al. 2008 Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family Fam Cancer 7 2 125 133 10.1007/s10689-007-9155-7 17657584 (Pubitemid 351871904)
46. YK Lim, et al. 2007 Identification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer Clin Genet 71 4 331 342 10.1111/j.1399-0004.2007.00773.x 1:STN:280: DC%2BD2s3mtFSqsA%3D%3D 17470134 (Pubitemid 46680798)
47. CG Song, et al. 2006 BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23 1 27 31 1:CAS:528:DC%2BD2sXjs1egsLg%3D 16456781
48. TT Law, et al. 2009 Telephone pre-anaesthesia assessment for ambulatory breast surgery Hong Kong Med J 15 3 179 182 1:STN:280:DC%2BD1MzptlSisg%3D%3D 19494372
49. M Kriege, et al. 2006 Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition Cancer 106 11 2318 2326 10.1002/cncr.21863 16615112 (Pubitemid 43787654)
50. DH Choi, et al. 2004 Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients J Clin Oncol 22 9 1638 1645 10.1200/JCO.2004.04. 179 1:CAS:528:DC%2BD2cXpsVWmu7c%3D 15117986 (Pubitemid 41079802)
51. SL Gomez AM France MM Lee 2004 Socioeconomic status, immigration/ acculturation, and ethnic variations in breast conserving surgery, San Francisco Bay area Ethn Dis 14 1 134 140 15002933
52. CM Julian-Reynier, et al. 2001 Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women Cancer 92 4 959 968 10.1002/1097-0142(20010815)92:4<959::AID-CNCR1406>3.0.CO;2-V 1:STN:280:DC%2BD3MvpvFanuw%3D%3D 11550171 (Pubitemid 32783086)
53. D Suen L Chow A Kwong 2008 Breast-conserving surgery in Hong Kong Chinese women World J Surg 32 12 2549 2553 10.1007/s00268-008-9586-9 18563485
54. JK Litton, et al. 2009 Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation Cancer 115 8 1598 1604 10.1002/cncr.24199 19280625
55. L Scheuer, et al. 2002 Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers J Clin Oncol 20 5 1260 1268 10.1200/JCO.20.5.1260 11870168 (Pubitemid 34177432)
56. EJ Meijers-Heijboer, et al. 2000 Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation Lancet 355 9220 2015 2020 10.1016/S0140-6736(00)02347-3 1:CAS:528:DC%2BD3cXksl2lt7s%3D 10885351
57. LN Lodder, et al. 2002 One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery) Breast Cancer Res Treat 73 2 97 112 10.1023/A:1015269620265 1:CAS:528: DC%2BD38XksFehtrw%3D 12088120 (Pubitemid 34548153)
58. A Uyei, et al. 2006 Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study Cancer 107 12 2745 2751 10.1002/cncr.22352 1:CAS:528:DC%2BD2sXovF2jsQ%3D%3D 17109443 (Pubitemid 44937026)
59. JA Ray LJ Loescher M Brewer 2005 Risk-reduction surgery decisions in high-risk women seen for genetic counseling J Genet Couns 14 6 473 484 10.1007/s10897-005-5833-5 16388328
60. JR Botkin, et al. 2003 Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing Am J Med Genet A 118A 3 201 209 10.1002/ajmg.a.10102 12673648
61. D Stirling, et al. 2005 Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system J Clin Oncol 23 24 5588 5596 10.1200/JCO.2005.05.097 16110018
62. CT Brekelmans, et al. 2001 Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk J Clin Oncol 19 4 924 930 1:STN:280:DC%2BD3M3gsFamtg%3D%3D 11181654
63. L Liberman 2004 Breast cancer screening with MRI-what are the data for patients at high risk? N Engl J Med 351 5 497 500 10.1056/NEJMe048117 1:CAS:528:DC%2BD2cXmtFaktLs%3D 15282358 (Pubitemid 38988600)
64. L Tabar, et al. 2004 Number needed to screen: lives saved over 20 years of follow-up in mammographic screening J Med Screen 11 3 126 129 10.1258/0969141041732175 1:STN:280:DC%2BD2cvptFGntw%3D%3D 15333270 (Pubitemid 39274093)
65. E Warner PA Causer 2005 MRI surveillance for hereditary breast-cancer risk Lancet 365 9473 1747 1749 10.1016/S0140-6736(05)66520-8 15910935 (Pubitemid 40744644)
66. ME Robson K Offit 2004 Breast MRI for women with hereditary cancer risk JAMA 292 11 1368 1370 10.1001/jama.292.11.1368 1:CAS:528:DC%2BD2cXns12rsLc%3D 15367560 (Pubitemid 39223232)
67. K Kerlikowske JS Brown DG Grady 1992 Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 80 4 700 707 1:STN:280:DyaK3s%2Fis1Sqtg%3D%3D 1407898
68. A Kwong, et al. 2008 Breast cancer in Chinese women younger than age 40: are they different from their older counterparts? World J Surg 32 2554 2561 10.1007/s00268-008-9589-6 18408960
69. A Kwong, et al. 2008 The acceptance and feasibility of breast cancer screening in the East Breast 17 1 42 50 10.1016/j.breast.2007.06.005 17720500 (Pubitemid 351228783)
70. C Nagata, et al. 2005 Mammographic density and the risk of breast cancer in Japanese women Br J Cancer 92 12 2102 2106 10.1038/sj.bjc.6602643 1:STN:280:DC%2BD2MzgvVWjsg%3D%3D 15956963 (Pubitemid 40966243)
71. G Ursin, et al. 1999 Breast cancer and oral contraceptive use in Asian-American women Am J Epidemiol 150 6 561 567 1:STN:280:DyaK1MvhvVGhtA%3D%3D 10489994
72. G Haars, et al. 2005 Measurements of breast density: no ratio for a ratio Cancer Epidemiol Biomarkers Prev 14 11 Pt 1 2634 2640 10.1158/1055-9965.EPI-05- 0824 16284389 (Pubitemid 41752726)
73. DS Buist, et al. 2004 Factors contributing to mammography failure in women aged 40-49 years J Natl Cancer Inst 96 19 1432 1440 10.1093/jnci/djh269 15467032 (Pubitemid 39429667)
74. CK Kuhl, et al. 2005 Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer J Clin Oncol 23 33 8469 8476 10.1200/JCO.2004.00.4960 16293877
75. SK Shah SK Shah KV Greatrex 2005 Current role of magnetic resonance imaging in breast imaging: a primer for the primary care physician J Am Board Fam Pract 18 6 478 490 10.3122/jabfm.18.6.478 16322412
76. A Kwong, et al. 2009 A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer Breast Cancer Res Treat 117 683 686 10.1007/s10549-009-0385-2 19353265
77. SK Plevritis, et al. 2006 Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging JAMA 295 20 2374 2384 10.1001/jama.295.20.2374 1:CAS:528:DC%2BD28Xlt1WksL8%3D 16720823 (Pubitemid 43788105)
78. KA Metcalfe, et al. 2005 The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation Fam Cancer 4 2 97 103 10.1007/s10689-005-4215-3 15951959 (Pubitemid 40897809)
79. C Foster, et al. 2007 Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up Br J Cancer 96 5 718 724 10.1038/sj.bjc.6603610 1:CAS:528:DC%2BD2sXisVGisrs%3D 17285126 (Pubitemid 46376618)
80. G Parmigiani D Berry O Aguilar 1998 Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2 Am J Hum Genet 62 1 145 158 10.1086/301670 1:CAS:528:DyaK1cXhsVGrsrc%3D 9443863 (Pubitemid 28093844)
81. AW Kurian GD Gong NM Chun, et al. 2008 Performance of BRCA1/2 mutation prediction models in Asian Americans J Clin Oncol 26 29 4752 4758 10.1200/JCO.2008.16.8310 1:CAS:528:DC%2BD1cXhtlSqsb7O 18779604
82. E Thirthagiri, et al. 2008 Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer Breast Cancer Res 10 4 R59 10.1186/bcr2118 1:CAS:528:DC%2BD1cXpvF2lsLo%3D 18627636
83. NY Rao Z Hu YM Yu, et al. 2008 Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients Breast Cancer Res Treat 116 3 563 570 10.1007/s10549-008-0181-4 18807178
84. Y Brandberg, et al. 2008 Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study J Clin Oncol 26 24 3943 3949 10.1200/JCO.2007.13.9568 18711183